For patients with moderate-to-severe, biologic-refractory psoriasis (failed or intolerant to anti-TNF, anti-IL-17, or anti-IL-23 agents) and persistent disease burden despite conventional systemic therapies, investigational stem-cell treatment may be worth considering if trial access is available. Efficacy is lower than modern biologics and remission durability is variable; this limits mainstream clinical adoption. For mild-to-moderate psoriasis controlled by topical or newer biologic approaches, conventional management remains first-line. Cost-benefit analysis requires honest assessment of realistic outcomes (50% improvement rather than complete clearance) and realistic remission durations (3–8 months).
Psoriasis is a chronic autoimmune inflammatory skin disease characterised by dysregulated T-cell responses (excessive Th17 and Th1 differentiation), keratinocyte hyperproliferation, and abnormal epidermal-dermal architecture. Genetic susceptibility (HLA-Cw6 and multiple polygenic loci) interacts with environmental triggers (stress, infection, trauma) to initiate disease. Placental mesenchymal stem cells and their exosomes modulate psoriasis through multiple mechanisms: IL-17 suppression, regulatory T-cell induction (enhanced Foxp3+ Treg populations), keratinocyte proliferation restraint via TGF-β signalling, and direct anti-inflammatory cytokine secretion (IL-10, TGF-β). Eleven registered clinical trials and zero actively recruiting protocols suggest mature but limited clinical translation, with focus on moderate-to-severe, refractory disease unsuitable for conventional topical or systemic approaches.
Am I a candidate? → · Psoriasis: full overview → · Psoriasis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita